A Multicenter, Randomized Controlled Study Comparing Keverprazan Hydrochloride-Amoxicillin Dual Therapy and Susceptibility-Guided Quadruple Therapy in Helicobacter Pylori Rescue Treatment

This study aims to evaluate the efficacy and safety of Keverprazan Hydrochloride combined with Amoxicillin in dual therapy compared to susceptibility-guided quadruple therapy in the treatment of Helicobacter pylori (H. pylori) infections requiring rescue therapy. H. pylori is a common infectious disease associated with peptic ulcers, gastric cancer, and mucosa-associated lymphoid tissue lymphoma. However, the increasing resistance of H. pylori to antibiotics has reduced the eradication rates of standard therapies.
Potassium-competitive acid blockers (P-CABs), such as Keverprazan Hydrochloride, provide faster and more sustained gastric acid suppression compared to traditional proton pump inhibitors (PPIs), making them a promising option for H. pylori treatment. This multicenter, randomized controlled trial will provide critical evidence comparing the effectiveness of Keverprazan-based dual therapy to susceptibility-guided quadruple therapy, aiming to establish optimized rescue therapy guidelines for H. pylori eradication.

Start Date15 Jan 2025

Sponsor / Collaborator

The Sixth Affiliated Hospital of Sun Yat-Sen University

[+3]

ChiCTR2400094257

/ SuspendedEarly Phase 1IIT

The Impact of Liposomal Bupivacaine on Recovery Quality After Iliac Fascia Block in Hip Fracture Surgery: A Prospective, Randomized, Controlled Clinical Study

Start Date01 Jan 2025

Sponsor / Collaborator

Guangdong Shenzhen Bao'An District People'S Hospital

100 Clinical Results associated with Guangdong Shenzhen Bao'An District People'S Hospital

0 Patents (Medical) associated with Guangdong Shenzhen Bao'An District People'S Hospital

Literatures (Medical) associated with Guangdong Shenzhen Bao'An District People'S Hospital

01 Jul 2023·Journal of Gastrointestinal Surgery

Risk Factors of Positive Resection Margin in Hepatectomy for Resectable Ruptured Hepatocellular Carcinoma: Risk Prediction and Prognosis

Article

Author: Zhang, Qiao ; Xia, Feng ; Huang, Zhiyuan ; Ndhlovu, Elijah ; Gao, Hengyi ; Zheng, Jun

BACKGROUND AND AIMClinical work has revealed that hepatectomy for resectable ruptured hepatocellular carcinoma (rHCC) has a relatively high percentage of positive resection margins found in postoperative pathology. It is necessary to evaluate the risk factors associated with R1 resection in patients undergoing hepatectomy for rHCC.METHODSA total of 408 patients with resectable rHCC originating from three centers undergoing surgery from January 2012 to January 2020 were consecutively enrolled in the study to study the prognostic impact of R1 resection using Kaplan-Meier plotting of survival curves. One center with 280 served as the training group, and the other two centers served as the validation group. Multivariate logistic regression analysis screened for variables affecting R1 and developed prediction models, and the models were tested in the validation cohort using the receiver operating characteristic curves (ROC) and calibration curves.RESULTSThe prognosis of rHCC patients with positive cut margins was worse than that of patients with R0 resection. Risk factors for R1 resection were tumor max length (OR = 2.668 [1.161-6.131]), microvascular invasion (MVI) (OR = 3.655 [1.766-7.566]), times of hepatic inflow occlusion (1/0:OR = 2.213 [1.113-4.399]; 2/0:OR = 5.723 [2.010-8.289]) and timing of hepatectomy (OR = 5.284 [2.394-9.661]), using tumor max length, times of HIO, and timing of hepatectomy to construct the nomogram, the area under the curve of the model was 0.810 (0.781-0.842) and 0.782 (0.752-0.805) in the training and validation groups, respectively, and the calibration curve of the model was basically on the 45° line.CONCLUSIONSThis study constructs a clinical model to predict R1 resection after hepatectomy for resectable rHCC, which can be used to better plan perioperative strategies for the incidence of R1 resection during hepatectomy.

Zhongguo Xiandai Putong Waike Jinzhan

Expression and significance of EMA and CD10 and E-Cadherin in colorectal adenocarcinoma with invasive micropapillary differentiation

Author: Gong, Jing-qing ; Cao, Duan-rong ; Zou, Gui-hua ; Liu, Yu-hong ; Li, Xiao-ming

To investigate the expression and significance of epithelial cell membrane antigen (EMA), CD10 and E-cadherin in colorectal adenocarcinoma with invasive micropapillary differentiation.A total of 130 patients with colorectal adenocarcinoma who underwent surgical treatment from Jan. 2016 to July 2018 were retrospectively selected as the research subjects.According to whether or not with invasive micropapillary differentiation, they were divided into the control group of 85 cases without invasive micropapillary differentiation and the observation group with invasive micropapillary differentiation of 45 cases.The expression levels of EMA, CD10 and E-Cadherin were detected and compared by immunohistochem.In the observation group, EMA was neg. 8.89%, pos. was 0, "inside-out" pos. pattern was 91.11%; CD10 was neg. 55.56%, pos. 33.33%, "inside-out" pos. pattern 11.11%; E-Cadherin pos. 68.89%, cell-to-cell contact surface Weakly pos. and interstitial lateral membrane neg. was 31.11%, neg. was 0; vascular infiltration was 95.56%; lymph node metastasis was 93.33%.In the control group, EMA neg. was 0, pos. 100.00%, "inside-out" pos. pattern was 0; CD10 was neg. 94.12%, pos. 5.88%, "inside-out" pos. pattern was 0; E-Cad-herin pos. 100.00%, the contact surface of cell-to-cell was weakly pos., the interstitial side membrane neg. was 0, and the neg. was 0; vascular infiltration was 6.25%; lymph node metastasis was 8.24%.There were statistically significant differences in each index between the two (P<0.05).Observing the expression levels of EMA, CD10 and E-Caderin in patients with colorectal adenocarcinoma can help to determine whether invasive micropapillary differentiation occurs and to evaluate the prognosis of patients.

100 Deals associated with Guangdong Shenzhen Bao'An District People'S Hospital

100 Translational Medicine associated with Guangdong Shenzhen Bao'An District People'S Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 15 Dec 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Guangdong Shenzhen Bao'An District People'S Hospital

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 15 Dec 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing